420 related articles for article (PubMed ID: 16202082)
1. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
[TBL] [Abstract][Full Text] [Related]
2. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Merigo E; Manfredi M; Meleti M; Guidotti R; Ripasarti A; Zanzucchi E; D'Aleo P; Corradi D; Corcione L; Sesenna E; Ferrari S; Poli T; Bonaninil M; Vescovi P
Acta Biomed; 2006 Aug; 77(2):109-17. PubMed ID: 17172192
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Migliorati CA; Schubert MM; Peterson DE; Seneda LM
Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
[TBL] [Abstract][Full Text] [Related]
5. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
Friedrich RE; Blake FA
Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
7. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Hay KD; Bishop PA
N Z Dent J; 2006 Mar; 102(1):4-9. PubMed ID: 16568881
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Dimitrakopoulos I; Magopoulos C; Karakasis D
Int J Oral Maxillofac Surg; 2006 Jul; 35(7):588-93. PubMed ID: 16687238
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals.
Magopoulos C; Karakinaris G; Telioudis Z; Vahtsevanos K; Dimitrakopoulos I; Antoniadis K; Delaroudis S
Am J Otolaryngol; 2007; 28(3):158-63. PubMed ID: 17499130
[TBL] [Abstract][Full Text] [Related]
10. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of maxillary osteonecrosis due to bisphosphonates using an Er:YAG (2940 nm) laser. Discussion of 17 clinical cases].
Vescovi P; Merigo E; Manfredi M; Meleti M; Fornaini C; Bonanini M; Rocca EP; De Moor RJ; Nammour S
Rev Belge Med Dent (1984); 2009; 64(2):87-95. PubMed ID: 19681350
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
Grant BT; Amenedo C; Freeman K; Kraut RA
J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
[TBL] [Abstract][Full Text] [Related]
13. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Gallego L; Junquera L
Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
17. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment.
Vescovi P; Merigo E; Meleti M; Fornaini C; Nammour S; Manfredi M
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):628-32. PubMed ID: 17524535
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Del Conte A; Bernardeschi P; La Ferla F; Turrisi G; D'Alessandro M; Montagnani F; Fiorentini G
J Oral Maxillofac Surg; 2010 May; 68(5):1179-82. PubMed ID: 20185222
[No Abstract] [Full Text] [Related]
19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
Leite AF; Figueiredo PT; Melo NS; Acevedo AC; Cavalcanti MG; Paula LM; Paula AP; Guerra EN
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):14-21. PubMed ID: 16831667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
